KRIBIOLISA™ Vedolizumab (ENTYVIO) ELISA
₹65,800.00
Enzyme Immunoassay for the estimation of Vedolizumab (ENTYVIO) in serum and plasma.
Key features:
1. Developed using highly specific monoclonal anti-idiotypic antibodies in a sandwich assay format
2. Validated as per international bioassay validation guidelines
3. Recovery: 80-120%
4. Precision CV <10%
The below Kit Insert is subject to change with the new lot of kits.
Availability: 3 – 4 Weeks | Pack Size: 1 x 96 wells
Powered by BiozDescription
Background:
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte 7 integrin, a key mediator of gastrointestinal inflammation. It is used in the treatment of moderate to severe active ulcerative colitis and Crohns disease for patients who have had an inadequate response with or lost response to, or were intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) or other conventional therapies. By blocking its primary target alpha beta 7 integrin, vedolizumab reduces inflammation in the gut.
Intended Use:
For Estimation of Vedolizumab (ENTYVIO) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Vedolizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Vedolizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Vedolizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Vedolizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!
Additional information
| Sample Type | Serum (100 ul), EDTA Plasma (100 ul), Heparin Plasma (100 ul), Citrate Plasma (100 ul) |
|---|---|
| Calibration Range | 0 ng/ml- 2000 ng/ml |
| Detection Method | Colorimetric |
| Specificity | 80% – 120% to Vedolizumab (ENTYVIO) |
| Cross Reactivity | < 0.5% cross-reactivity observed with related biomarker. |
| Interference | No significant interference observed with available related molecules. |
| Regulatory Status | Research Use Only |
| Research Area | Biosimilars / Therapeutic Drug Monitoring |
| Entez Gene ID | LDP 02 Human |
| ELISA Type | Direct Sandwich Assay |
| Storage Temperature | Store the unopened product at 2-8 Deg C. Opened products to be stored as per temperatures indicated on the datasheet. |
| Validation | The kit uses a biosimilar research grade standard / calibrator. The standard / calibrator has been validated against WHO/NIBSC standard and/or against commercially sourced innovator drug where available. Please refer to the IFU for more details. |
| Disclaimer | Trade name indicated is for reference purposes only. It does not reflect any licences or patent usage. The tradename is the registered trademark of the respective owners only. |
| Long Name | Protein Based Therapies – Monoclonal Antibody |